Home  >  News
you can get e-magazine links on WhatsApp.Click here
biopol
News
  DaVita acquires of transplant software company, MedSleuth,   January 19, 2022
  Jacobio Pharma gets US FDA approval to begin phase I/IIa trial of for Aurora A inhibitor, JAB-2485 to treat patients with advanced solid tumours,   January 18, 2022
  US FDA approves Ascletis’ IND application for envafolimab to treat chronic hepatitis B,   January 18, 2022
  Hikma Pharma acquires Canadian sterile injectable assets of Teligent for $45.75 million,   January 18, 2022
  US FDA accepts and grants priority review status to Daiichi Sankyo & AstraZeneca’s sBLA of Enhertu for patients with HER2 positive metastatic breast cancer treated with a prior anti-her2-based regimen,   January 18, 2022
  GlaxoSmithKline rejects £50 billion bid from Unilever for consumer healthcare unit,   January 17, 2022
  WHO recommends two new drugs, baricitinib & sotrovimab to treat Covid-19,   January 17, 2022
  Pfizer’s once-daily JAK1 inhibitor, Cibinqo receives US FDA approval to treat with moderate-to-severe atopic dermatitis,   January 17, 2022
  Biognosys’ proteomics facility gets GLP certification from Swiss health authorities,   January 15, 2022
  Behavioral Health Group acquires Center for Behavioral Health,   January 15, 2022
  Gracell Biotech to open newly established Innovation Center in US during first quarter of 2022,   January 14, 2022
  Malvern Panalytical acquires Switzerland-based bioanalysis sensor company, Creoptix,   January 13, 2022
  Vertex Pharma gets European label extension approval for Kaftrio in combo with ivacaftor to treat children with CF ages 6 to 11 years,   January 13, 2022
  US FDA approves SNIPR BIOME’s IND application for new CRISPR therapy, SNIPR001 to treat E. coli infections,   January 12, 2022
  Ascletis files US IND application for oral PD-L1 small molecule inhibitor ASC61 to treat advanced solid tumours,   January 11, 2022
  Hikma launches new outsourced sterile compounding business, Hikma 503B,   January 11, 2022
  AbbVie seeks US FDA & European approvals for upadacitinib to treat non-radiographic axial spondyloarthritis,   January 10, 2022
  US FDA grants fast track status to Dynacure’s DYN101 to treat myotubular and centronuclear myopathies,   January 08, 2022
  BeiGene’s anti-PD-1 antibody tislelizumab gets China NMPA approval to treat patients with locally advanced or metastatic NSCLC,   January 08, 2022
  Eisai grants exclusive rights of anticancer agent H3B-8800 to Roivant Sciences,   January 08, 2022

 Back
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |